❓WHAT HAPPENED: Nine major pharmaceutical companies have agreed to lower drug prices in deals with President Donald J. Trump.
👤WHO WAS INVOLVED: President Trump and pharmaceutical companies, including Pfizer, AstraZeneca, Eli Lilly, Novo Nordisk, Merck, and others.
📍WHEN & WHERE: The agreements were finalized on Friday in the United States.
💬KEY QUOTE: “This represents the greatest victory for patient affordability in the history of American health care, by far, and every single American will benefit.” – Donald Trump
🎯IMPACT: The agreements aim to reduce U.S. drug prices and include selling treatments to Medicaid patients at the lowest “most favored nation” price.
President Donald J. Trump has finalized agreements with nine major U.S. and European pharmaceutical companies to lower their drug prices for American consumers, in line with the prices they charge in other countries. The agreements with Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, and Sanofi were announced by President Trump during an event at the White House on Friday afternoon alongside the executive leadership of the drug companies.
“As of today, 14 out of the 17 largest pharmaceutical companies … have now agreed to drastically lower drug prices for … the American people and the American patients,” Trump said at the event, adding: “This represents the greatest victory for patient affordability in the history of American health care, by far, and every single American will benefit.”
Absent from the group were Johnson & Johnson, AbbVie, and Regeneron. However, the President noted that executives from Johnson & Johnson would be at the White House next week to finalize their own agreement.
The establishment of most-favored-nation pricing models is expected to substantially lower prescription costs for Americans as the pharmaceutical deals take effect. Trump has accused other nations of engaging in what he terms “global freeloading,” in which foreign drug prices are essentially subsidized through higher costs being passed on to American consumers.
The agreements are a significant win for the Trump White House, as the industry’s massive trade association, PhRMA, has continually pushed hard against the most-favored-nation pricing policy.
MUST WATCH: Leaders from nine major pharmaceutical companies—Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, and Sanofi—discuss moves to lower prescription drug prices for Americans.
Completely unprecedented. pic.twitter.com/sBjCfKO41Z
— Rapid Response 47 (@RapidResponse47) December 19, 2025
Join Pulse+ to comment below, and receive exclusive e-mail analyses.